3 Molecular Diagnostics Company, Innerwear Maker and Pharma Ingredients Maker Stocks With a Strong Future Roadmap: Molbio Diagnostics, Dollar Industries and Acutaas Chemicals
- November 13, 2026
- Posted by: Neeraj Pandey
- Category: Best Stocks
Molbio Diagnostics, Dollar Industries and Acutaas Chemicals: ROE of 11.3% to 21.5% and FY22 to FY26 revenue CAGR of 8.7% to 27.5%. Prices as of 12 Nov 2026.
Quick Answer
The three diagnostic kit, innerwear and API stocks to watch are Molbio Diagnostics, Dollar Industries and Acutaas Chemicals. Their return on equity ranges from 11.3% to 21.5%, and their revenue compound annual growth from FY22 to FY26 ranges from 8.7% to 27.5%. Acutaas Chemicals leads on both return on equity at 21.5% and revenue growth at 27.5% a year. Prices are based on the 12 November 2026 close, and this article is educational, not investment advice.
Diagnostic kit, innerwear and API stocks give investors a way to track businesses that sit close to everyday demand in India. Molbio Diagnostics, Dollar Industries and Acutaas Chemicals cover a molecular diagnostics company, an innerwear maker and a pharma ingredients maker.
This list covers three diagnostic kit, innerwear and API stocks with complete current figures: Molbio Diagnostics, Dollar Industries and Acutaas Chemicals. Every figure comes from the latest reported financials and the 12 November 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are Diagnostic Kit, Innerwear and API Stocks?
Diagnostic kit, innerwear and API stocks are listed companies that make molecular diagnostic test kits and instruments, make and sell innerwear and casual wear, and make active pharmaceutical ingredients and intermediates for drug firms. Their earnings depend on test volumes, household spending and drug sourcing.
Diagnostic Kit, Innerwear and API Stocks at a Glance
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE (%) | D/E |
|---|---|---|---|---|---|---|
| Molbio Diagnostics | 1,394.1 | 16,605 | 101.2 | 59.6 | 14.2 | 0.38 |
| Dollar Industries | 268.88 | 1,489 | 13.3 | 35.2 | 11.3 | 0.31 |
| Acutaas Chemicals | 3,996.1 | 31,066 | 70.8 | 36.2 | 21.5 | 0.02 |
On valuation, Dollar Industries trades at a P/E below the industry P/E, while Molbio Diagnostics and Acutaas Chemicals trade above it, which reflects the growth the market already expects. Readers comparing diagnostic kit, innerwear and API stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.
Why Do Diagnostic Kit, Innerwear and API Stocks Have a Strong Roadmap in India?
Diagnostic kit, innerwear and API stocks have a strong roadmap in India because wider use of molecular testing, rising demand for branded innerwear and growing global sourcing of pharma ingredients keep widening the market for these companies.
- Molecular diagnostics. Doctors rely more on precise tests.
- Innerwear. Shoppers prefer trusted brands.
- Pharma ingredients. Drug makers need reliable specialty inputs.
Why Molbio Diagnostics Features Among These Diagnostic Kit, Innerwear and API Stocks
Among the diagnostic kit, innerwear and API stocks on this list, Molbio Diagnostics, based in Goa, develops the Truenat platform, a portable molecular diagnostics system that delivers lab-grade PCR results at the point of care, with strong use in tuberculosis testing.
The company has a return on equity of 14.2%, a debt to equity ratio of 0.38 and a market capitalisation of Rs 16,605 crore. The stock trades at a P/E of 101.2, above the industry P/E of 59.6.
Revenue rose from Rs 782 crore in FY22 to Rs 1,455 crore in FY26, a compound annual growth rate of 16.8%. Net profit grew from Rs 83.5 crore in FY24 to Rs 164 crore in FY26, which works out to a compound annual growth rate of 40.2%.
Roadmap: Its roadmap centres on widening the Truenat test menu beyond TB, pushing into more countries through government and donor programmes, and building recurring revenue from test chips and consumables on top of the installed analyser base.
What to watch: Order timing from public health programmes can be lumpy, so look at annual rather than single-quarter trends.
Why Dollar Industries Features Among These Diagnostic Kit, Innerwear and API Stocks
Among the rapid test maker, knitwear and drug ingredient shares on this list, Dollar Industries is a Kolkata-based innerwear and athleisure company that sells under brands such as Big Boss, Force NXT, Missy and Dollar Bigboss.
Revenue rose from Rs 1,349 crore in FY22 to Rs 1,885 crore in FY26, a compound annual growth rate of 8.7%. Net profit grew from Rs 52.5 crore in FY23 to Rs 107 crore in FY26, which works out to a compound annual growth rate of 26.9%.
In the June 2026 quarter, revenue grew 1.5% year on year to Rs 406 crore, while net profit rose 20.4% to Rs 26.2 crore. The company has a return on equity of 11.3%, a debt to equity ratio of 0.31 and a market capitalisation of Rs 1,489 crore. The stock trades at a P/E of 13.3, below the industry P/E of 35.2.
Roadmap: The company has a wide distribution network across the country and has widened its range into women’s wear and athleisure. Brand extensions and a growing share of premium products support its plans.
What to watch: Track the growth in premium categories and the distributor network expansion.
Why Acutaas Chemicals Features Among These Diagnostic Kit, Innerwear and API Stocks
Among the three companies on this list, Acutaas Chemicals, earlier known as Ami Organics, is a Surat-based speciality chemicals company that makes advanced pharmaceutical intermediates, battery electrolyte additives and active ingredients for global customers.
Revenue rose from Rs 523 crore in FY22 to Rs 1,381 crore in FY26, a compound annual growth rate of 27.5%. Net profit grew from Rs 72.0 crore in FY22 to Rs 356 crore in FY26, which works out to a compound annual growth rate of 49.2%.
The company has a return on equity of 21.5%, a debt to equity ratio of 0.02 and a market capitalisation of Rs 31,066 crore. The stock trades at a P/E of 70.8, above the industry P/E of 36.2.
Roadmap: The company is expanding its range of advanced intermediates and building new capacity for battery materials and innovator pharma supply. Long-term supply relationships with global customers support its order flow.
What to watch: Follow capacity additions, new product approvals and export orders.
Molbio Diagnostics vs Dollar Industries vs Acutaas Chemicals on Key Financials
The table below sets the three diagnostic kit, innerwear and API stocks side by side on revenue, profit and margin, using reported figures.
| Company | FY22 Revenue (Rs Cr) | FY26 Revenue (Rs Cr) | Revenue CAGR (FY22-FY26) | FY26 Net Profit (Rs Cr) | FY26 Net Margin |
|---|---|---|---|---|---|
| Molbio Diagnostics | 782 | 1,455 | 16.8% | 164 | 11.3% |
| Dollar Industries | 1,349 | 1,885 | 8.7% | 107 | 5.7% |
| Acutaas Chemicals | 523 | 1,381 | 27.5% | 356 | 25.8% |
Acutaas Chemicals posts the highest return on equity in this group at 21.5%. Dollar Industries has the largest FY26 revenue at Rs 1,885 crore, and Acutaas Chemicals shows the fastest revenue growth with a 27.5% compound annual rate. A useful habit with diagnostic kit, innerwear and API stocks is to check each new quarterly result against the capacity plans the company described earlier.
Key Risks to Check Before Investing in Diagnostic Kit, Innerwear and API Stocks
Every theme carries risks that deserve a check before any decision. For these diagnostic kit, innerwear and API stocks, the main points are:
- Test volumes. Footfall and test mix can vary with seasons.
- Consumer spending. Sales follow festivals, incomes and consumer mood.
- Regulatory approvals. Plant inspections and approvals can affect supplies.
Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.
Use the Univest Stock Screener to filter diagnostic kit, innerwear and API stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.
Final Thoughts on Diagnostic Kit, Innerwear and API Stocks
Diagnostic kit, innerwear and API stocks work best when investors track growth, valuation and return on equity side by side. Molbio Diagnostics, Dollar Industries and Acutaas Chemicals each have a clear plan to grow. Based on the 12 November 2026 close, Molbio Diagnostics trades at Rs 1,394.1, Dollar Industries at Rs 268.88 and Acutaas Chemicals at Rs 3,996.1.
Download the Univest iOS App or Univest Android App to track diagnostic kit, innerwear and API stocks, set price alerts and get research-backed stock ideas.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
What are diagnostic kit, innerwear and API stocks?
Ans. Diagnostic kit, innerwear and API stocks are listed companies that make molecular diagnostic test kits and instruments, make and sell innerwear and casual wear, and make active pharmaceutical ingredients and intermediates for drug firms. Their earnings depend on test volumes, household spending and drug sourcing. This list looks at three of them, Molbio Diagnostics, Dollar Industries and Acutaas Chemicals, using reported FY22 to FY26 financials and the 12 November 2026 closing prices.
Which diagnostic kit, innerwear and API stocks are covered in this list?
Ans. This list covers Molbio Diagnostics, Dollar Industries and Acutaas Chemicals. Based on the 12 November 2026 close, Molbio Diagnostics traded at Rs 1,394.1, Dollar Industries at Rs 268.88 and Acutaas Chemicals at Rs 3,996.1. Their return on equity ranges from 11.3% to 21.5%, and their revenue compound annual growth from FY22 to FY26 ranges from 8.7% to 27.5%.
Why do diagnostic kit, innerwear and API stocks have a strong future roadmap in India?
Ans. Diagnostic kit, innerwear and API stocks have a strong roadmap in India because wider use of molecular testing, rising demand for branded innerwear and growing global sourcing of pharma ingredients keep widening the market for these companies. The main drivers are as follows. Molecular diagnostics. Doctors rely more on precise tests. Innerwear. Shoppers prefer trusted brands. Pharma ingredients. Drug makers need reliable specialty inputs. Together these factors give the companies on this list a visible path for growth over the coming years.
How has Molbio Diagnostics performed financially?
Ans. Revenue rose from Rs 782 crore in FY22 to Rs 1,455 crore in FY26, a compound annual growth rate of 16.8%. Net profit grew from Rs 83.5 crore in FY24 to Rs 164 crore in FY26, which works out to a compound annual growth rate of 40.2%. The company has a return on equity of 14.2%, a debt to equity ratio of 0.38 and a market capitalisation of Rs 16,605 crore. The stock trades at a P/E of 101.2, above the industry P/E of 59.6. Looking ahead, its roadmap centres on widening the Truenat test menu beyond TB, pushing into more countries through government and donor programmes, and building recurring revenue from test chips and consumables on top of the installed analyser base.
How has Dollar Industries performed financially?
Ans. Revenue rose from Rs 1,349 crore in FY22 to Rs 1,885 crore in FY26, a compound annual growth rate of 8.7%. Net profit grew from Rs 52.5 crore in FY23 to Rs 107 crore in FY26, which works out to a compound annual growth rate of 26.9%. In the June 2026 quarter, revenue grew 1.5% year on year to Rs 406 crore, while net profit rose 20.4% to Rs 26.2 crore. The company has a return on equity of 11.3%, a debt to equity ratio of 0.31 and a market capitalisation of Rs 1,489 crore. The stock trades at a P/E of 13.3, below the industry P/E of 35.2. Looking ahead, the company has a wide distribution network across the country and has widened its range into women’s wear and athleisure. Brand extensions and a growing share of premium products support its plans.
How has Acutaas Chemicals performed financially?
Ans. Revenue rose from Rs 523 crore in FY22 to Rs 1,381 crore in FY26, a compound annual growth rate of 27.5%. Net profit grew from Rs 72.0 crore in FY22 to Rs 356 crore in FY26, which works out to a compound annual growth rate of 49.2%. The company has a return on equity of 21.5%, a debt to equity ratio of 0.02 and a market capitalisation of Rs 31,066 crore. The stock trades at a P/E of 70.8, above the industry P/E of 36.2. Looking ahead, the company is expanding its range of advanced intermediates and building new capacity for battery materials and innovator pharma supply. Long-term supply relationships with global customers support its order flow.
What risks should investors check before buying diagnostic kit, innerwear and API stocks?
Ans. Investors should check a few risks before buying diagnostic kit, innerwear and API stocks. Test volumes. Footfall and test mix can vary with seasons. Consumer spending. Sales follow festivals, incomes and consumer mood. Regulatory approvals. Plant inspections and approvals can affect supplies. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.
Is this list of diagnostic kit, innerwear and API stocks investment advice?
Ans. No. This article is educational and uses publicly available data as of the 12 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.
